BioCentury | Dec 22, 2017
Clinical News

Eisai reports Phase Ib/II data for Halaven plus Keytruda in TNBC

...triple-negative breast cancer (TNBC) in the Phase Ib/II ENHANCE 1 (KEYNOTE-150) trial showing that Halaven eribulin mesylate...
...or metastatic liposarcoma following an anthracycline-containing regimen. Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Product: Halaven eribulin mesylate...
...duration of response and CBR in PD-L1-positive patients Status: Phase Ib/II data Milestone: NA Jaime De Leon E7389 eribulin mesylate Halaven Keytruda MK-3475 pembrolizumab Eisai...
BioCentury | Nov 7, 2016
Company News

Halaven sales and marketing update

...The U.K.’s NICE issued a final appraisal determination (FAD) recommending the use of Halaven eribulin mesylate to...
BioCentury | Aug 15, 2016
Clinical News

Halaven eribulin mesylate regulatory update

...over 60 countries to treat breast cancer. Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Product: Halaven eribulin mesylate...
BioCentury | May 30, 2016
Clinical News

Halaven eribulin mesylate: Phase III data

...about 60 countries to treat breast cancer. Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Product: Halaven eribulin mesylate...
BioCentury | May 16, 2016
Clinical News

Halaven eribulin mesylate regulatory update

...after >=1 chemotherapeutic regimen for advanced disease. Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Product: Halaven eribulin mesylate...
BioCentury | Apr 25, 2016
Clinical News

Halaven eribulin mesylate regulatory update

...after >=1 chemotherapeutic regimen for advanced disease. Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Product: Halaven eribulin mesylate...
BioCentury | Mar 7, 2016
Clinical News

Eribulin mesylate regulatory update

...Eisai said Japan approved Halaven eribulin mesylate to treat soft tissue sarcoma (STS). The synthetic analog of...
...unresectable or metastatic liposarcoma (see BioCentury, Feb. 8). Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Product: Eribulin mesylate...
BioCentury | Feb 22, 2016
Company News

Piqur, Eisai deal

...Piqur will conduct a Phase I/IIb trial combining breast cancer drug Halaven eribulin mesylate from Eisai with...
BioCentury | Feb 8, 2016
Clinical News

Halaven eribulin mesylate regulatory update

...FDA approved an sNDA from Eisai for Halaven eribulin mesylate to treat unresectable or metastatic liposarcoma in...
...regimens for the treatment of metastatic disease. Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Product: Halaven eribulin mesylate...
BioCentury | Dec 21, 2015
Clinical News

Mifepristone: Additional Phase I/II data

...U.S. Phase I/II trial showed that once-daily 300 mg mifepristone plus 1.1 mg/m 2 Halaven eribulin mesylate...
Items per page:
1 - 10 of 80